Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
1201 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Australia 71
1202 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 76
1203 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Canada 66
1204 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 74
1205 Apheresis Allogeneic Morbus Hodgkin Hematology 2025 Standard Therapy Germany 21
1206 Apheresis Allogeneic Myelodysplastic Disorders Hematology 2025 Standard Therapy France 66
1207 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy USA 65
1208 Apheresis Allogeneic T Lymphoblastic Lymphoma Hematology 2025 Standard Therapy Portugal 25
1209 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Romania 29
1210 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 37
1211 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 49
1212 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 32
1213 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 72
1214 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 43
1215 Apheresis Allogeneic Hodking lymphoma Hematology 2025 Standard Therapy Serbia 32
1216 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Canada 66
1217 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 71
1218 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 66
1219 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 68
1220 Apheresis Allogeneic OMDS/ Myeloproliferative Neoplasie Hematology 2025 Standard Therapy Switzerland 46
1221 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 3
1222 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 75
1223 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 58
1224 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Greece 63
1225 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 64
1226 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 65
1227 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Spain 49
1228 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 30
1229 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 66
1230 Apheresis Allogeneic Chronic Lymphocyte Leukemia Hematology 2025 Standard Therapy Canada 55
1231 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2025 Standard Therapy USA 64
1232 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 16
1233 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy USA 73
1234 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Ukraine 47
1235 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 64
1236 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 67
1237 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2025 Standard Therapy USA 65
1238 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 58
1239 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy Germany 57
1240 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy RUSSIAN FEDERATION 22
1241 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Ukraine 33
1242 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Slovakia 41
1243 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Greece 54
1244 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Ukraine 46
1245 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Argentina 26
1246 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 70
1247 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 59
1248 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 34
1249 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Norway 53
1250 Apheresis Allogeneic Other Immune System Hematology 2025 Standard Therapy USA 19
1251 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 6
1252 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 68
1253 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 72
1254 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 64
1255 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy United Kingdom 33
1256 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Italy 63
1257 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Lithuania 33
1258 Apheresis Autologous Central Nervous System Lymphoma Hematology 2025 Standard Therapy Germany 61
1259 Apheresis Allogeneic Acute lymphocytic leukemia Hematology 2025 Standard Therapy Germany 51
1260 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 64
1261 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 54
1262 Apheresis Autologous Testicular tumor Hematology 2025 Standard Therapy Germany 42
1263 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 52
1264 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 49
1265 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 73
1266 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 62
1267 Apheresis Autologous Lymphoma Hodgkin Hematology 2025 Standard Therapy Portugal 39
1268 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 60
1269 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 70
1270 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 64
1271 Apheresis Autologous T-Cell Lymphoma Hematology 2025 Standard Therapy Germany 60
1272 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 62
1273 Apheresis Autologous Mantle Cell Lymphoma Hematology 2025 Standard Therapy Germany 60
1274 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 43
1275 Apheresis Allogeneic Myeofibrosis Hematology 2025 Standard Therapy Poland 37
1276 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Russia 22
1277 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy NETHERLANDS 66
1278 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 57
1279 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 56
1280 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 78
1281 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 65
1282 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 53
1283 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Portugal 41
1284 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 56
1285 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 22
1286 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 36
1287 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Canada 65
1288 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 71
1289 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Sweden 73
1290 Apheresis Allogeneic NK LGL Leukemia Hematology 2025 Standard Therapy USA 42
1291 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Italy 29
1292 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 71
1293 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 68
1294 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Czechia 64
1295 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 10
1296 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Brazil 57
1297 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Lithuania 21
1298 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Lithuania 54
1299 Apheresis Allogeneic Richter Transformation From CLL Hematology 2025 Standard Therapy Poland 55
1300 Apheresis Allogeneic Richter Transformation From CLL Hematology 2025 Standard Therapy Poland 63
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?